Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058558 | 0.86 | CA12 (0.32) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL564061 | 0.83 | — | — | |
| SCHEMBL4101601 | 0.83 | — | — | |
| SCHEMBL24152304 | 0.81 | — | — | |
| SCHEMBL19335882 | 0.81 | — | — | |
| SCHEMBL19215251 | 0.81 | — | — | |
| SCHEMBL1024573 | 0.76 | NOS3 (0.31) | — | |
| SCHEMBL10092225 | 0.76 | — | — | |
| SCHEMBL12256919 | 0.76 | — | — | |
| SCHEMBL25017277 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399575-B2 | Crosslinkable materials based on organosilicon compounds | WACKER CHEMIE AG (DE) | 2013-03-19 | — | — | US | claimed |
| EP-1686990-B1 | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | US ARMY MED RES MAT COMMAND (US) | 2012-09-19 | — | — | EP | claimed |
| US-20120004364-A1 | Crosslinkable Materials Based On Organosilicon Compounds | WACKER CHEMIE AG (DE) | 2012-01-05 | — | — | US | claimed |
| CN-101959876-A | 2-aminoquinolines | HOFFMANN LA ROCHE | 2011-01-26 | — | — | CN | claimed |
| WO-2007142700-A1 | COPPER (I) AMIDINATES AND GUANIDINATES FOR FORMING COPPER THIN FILMS | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | claimed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | claimed |
| CN-1117291-A | 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections | UPJOHN CO (US) | 1996-02-21 | — | — | CN | claimed |
| US-12465592-B2 | Structured encapsulated silicon-containing particles | SISAF LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| EP-3946279-B1 | STRUCTURED ENCAPSULATED SILICON-CONTAINING PARTICLES | SISAF LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0572635-B1 | COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NAT RECH SCIENT (FR) | 1996-12-27 | — | — | EP | disclosed |
| EP-0572635-A1 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME. | CENTRE NAT RECH SCIENT (FR) | 1993-12-08 | — | — | EP | disclosed |
| EP-0572635-A4 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME. | CENTRE NAT RECH SCIENT (FR) | 1993-09-17 | — | — | EP | disclosed |
| WO-1993010102-A1 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA2 4784/4885 |
| US-12465592-B2 | Structured encapsulated silicon-containing particles | SGMS1, SGMS2, SMURF1 | CA12 1978/4885CA1 2014/4885CA2 4180/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | CA12 399/4885CA1 1330/4885CA2 2150/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA1 4251/4885CA2 4784/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | CA12 4043/4885CA1 4560/4885CA2 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.